The online version of this article (https://doi.org/10.1007/s40200-019-00400-7) contains supplementary material, which is available to authorized users.
ET-traps have a very high binding affinity.
ET-traps significantly return different markers of pathology to basal levels (have a therapeutic effect) in an in vivo model of diabetes.
ET-traps are non-toxic.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Type 1 diabetes is a serious, lifelong condition where the body’s blood glucose level increases because of the body’s inability to make insulin. An important consequence of this is the increased expression of extracellular matrix proteins, such as fibronectin and collagen 4α1, in key tissues and organs like the heart and kidneys. Diabetes is also associated with increased plasma levels of the vasoactive peptide endothelin (ET)-1. This further aggravates the expression of the ECM proteins. There are also important consequences of increased glucose and ET-1 levels in diabetes on the heart, termed diabetic cardiomyopathy.
We have previously reported the development of ET-traps, which potently and significantly reduce pathological levels of ET-1. In this study, we tested the in vivo therapeutic potential of ET-traps for type 1 diabetes using the B6 mouse model.
Following subcutaneous administration of ET-traps 3 times a week, over a 2 month period, the 500 nM dose of ET-traps gave a significant reduction in collagen 4α1 expression in the heart and kidney, returning it back to control, non-diabetic levels at both the mRNA and protein levels. The expression of fibronectin mRNA is also returned to control levels with the 500 nM dose of ET-traps. The efficacy of ET-traps for type 1 diabetes was further evinced by immunohistochemistry data, echocardiography studies (measuring left ventricular systolic function and diastolic dysfunction) and a measure of urine creatinine and albumin levels. In all analyses, the 500 nM dose of ET-traps returns the different measures to control, non-diabetic levels.
Data from this study show that in a mouse model ET-traps have a potent and significant therapeutic effect on diabetes disease pathology. Future studies could further evaluate the use of ET-traps as a therapy for diabetes, including taking them through clinical trials.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
ESM 1 (PDF 540 kb)40200_2019_400_MOESM1_ESM.pdf
Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(1):a007732. CrossRef
Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem. 2011;57(2):176–85. CrossRef
Escher S, Sandholzer H. The epidemiology of type 1 diabetes mellitus. 2013;1–22.
Maahs DM, et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin N Am. 2010;39(3):481–97. CrossRef
Fernandes JR, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016;117(2016):48–54.
Melmed S, et. al. Williams textbook of endocrinology, 2011.
Law B, et al. Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal. 2012;18(1):22–34. CrossRef
Evans T, et al. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49(4):662–6. CrossRef
Chen S, et al. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol. 2003;284(2):C263–72. CrossRef
Jain A, et al. Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes. J Diabetes Metab Disord. 2018.
Simonson MS, Ismail-Beigi F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem. 2011;286(13):11003–8. CrossRef
Seligman BG, et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23(9):1395–400. CrossRef
Schneider JG, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967–72. CrossRef
Stehouwer CD, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34(1):55–68. CrossRef
De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care. 2000;3(6):453–67. CrossRef
Deanfield J, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(1):7–17. CrossRef
Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76(1):8–18. CrossRef
He, Z. Role of PKC[delta] and Endothelin-1 in Diabetic Cardiomyopathy. In 66th Scientific Sessions 2006. American Diabetes Association.
Jun R, Chiming W. New sniper assignment for a celebrity-role of endothelin-1 in diabetic cardiomyopathy. Journal of Cardiothoracic - Renal Research. 2006;1(1):30–2. CrossRef
Seymour, T., What is diabetic nephropathy?, in Medical News Today. 2017.
A Shahriar, et al. Diabetic nephropathy, Pathophysiology and complications of diabetes mellitus; 2012.
Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010;1(2):48–56. CrossRef
Georgianos PI, Agarwal R. Endothelin a receptor antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(5):338–44. CrossRef
Chen S, et al. miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes. PLoS One. 2017;12(3):e0173918. CrossRef
Thomas AA, Feng B, Chakrabarti S. ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications. Am J Physiol Endocrinol Metab. 2018;314(3):E191–200. CrossRef
Feng B, et al. miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes. J Mol Cell Cardiol. 2017;105:70–6. CrossRef
Chen S, et al. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab. 2003;284(6):E1089–97. CrossRef
Wu Y, et al. ERK5 contributes to VEGF alteration in diabetic retinopathy. J Ophthalmol. 2010;2010:465824.
Roy S, et al. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory; 1990;87(1):404–8.
Morrish NJ, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):S14–21. CrossRef
Lip G, Hall J. Comprehensive hypertension. ScienceDirect. 2007.
Mishra PK, et al. Diabetic cardiomyopathy: an Immunometabolic perspective. Front Endocrinol (Lausanne). 2017;8:72. CrossRef
Cosson S, Kevorkian JP. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab. 2003;29(5):455–66. CrossRef
Slavica M, Biljana L. Contemporary echocardiographic techniques in early detection of diabetic cardiomyopathy. Journal of Cardiology and Current Research. 2014.
Townsend JC. Increased albumin excretion in diabetes. J Clin Pathol. 1990;43(1):3–8. CrossRef
Kos I, Prkačin I. Diabetic nephropathy as a cause of chronic kidney disease. Acta Med Croatica. 2014;68(4–5):375–81.
Genovese F, et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair. 2014;7(1):4. CrossRef
- In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes
- Springer International Publishing
Journal of Diabetes & Metabolic Disorders
Elektronische ISSN: 2251-6581
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II